Skip to main navigation Skip to search Skip to main content

Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran

  • Tanja Fens*
  • , Lisa de Jong
  • , Bregt Kappelhoff
  • , Cornelis Boersma
  • , Maarten J. Postma
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases